June 15, 2026

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

Conexiant

June 15, 2026

The Science of Listening

Why patient voices must shape rare disease innovation

The Medicine Maker

June 12, 2026

High-Dose Vitamin C Could Pose Risk in Severe Burns

“High-dose intravenous vitamin C administered early after injury did not reduce organ dysfunction or [mortality] and should not be a treatment in severe burns.”

Conexiant

June 11, 2026

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Conexiant

June 09, 2026

Study Reassures on Safety of Early NSAID Use

A large cohort found no adjusted link to major congenital malformations, but questions remain for miscarriage, later pregnancy, and other outcomes.

Conexiant

June 08, 2026

FDA Expands Marstacimab Indication in Hemophilia A and B

Phase 3 BASIS and BASIS KIDS data supported the expanded indication across pediatric and inhibitor-pretreated populations.

Conexiant

June 05, 2026

Congo Ebola Outbreak Strains Care Delivery

“We live with fear in our stomachs"

Kff Health News

June 05, 2026

Youth Vaping Is "Predictable" by Design

Product engineering, not individual choice, is driving adolescent nicotine dependence, researchers argue.

Conexiant

June 05, 2026

Can Finerenone Alter Glomerular Disease Trajectory?

A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases.

Conexiant

June 03, 2026

How Many US Clinicians Come From Banned Countries?

Counties with at least one clinician from a banned country were more likely to be designated primary care shortage areas.

Conexiant